Tumor distribution of bromodeoxyuridine-labeled cells is strongly dose dependent

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5707-5711

  Kyle, Alastair H ^a   Huxham, Lynsey A ^a   Baker, Jennifer H E ^a   Burston, Helen E ^a   Minchinton, Andrew I ^a  

^a BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; CYCLINE; KI 67 ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CYCLE S PHASE; CELL DEATH; CELL LABELING; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG TUMOR LEVEL; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; BROMODEOXYURIDINE; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS;

EID: 0141731335     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Djordjevic, D., and Szybalski, W. Genetics of human cell lines. III. Incorporation of 5-bromo and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect of radiation sensitivity. J. Exp. Med., 112: 509-531, 1960.
2. Kinsella, T. J., Russo, A., Mitchell, J. B., Rowland, J., Jenkins, J., Schwade, J., Myers, C. E., Collins, J. M., Speyer, J., and Komblith, P. A Phase I study of intermittent intravenous bromodeoxyuridine (BUdR) with conventional fractionated irradiation. Int. J. Radiat. Oncol. Biol. Phys., 10: 69-76, 1984.
3. Ensminger, W. D., Walker, S. C., Stetson, P. L., Wagner, J. G., Knol, J. A., Lawrence, T. S., and Andrews, J. C. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2′-deoxyuridine. Cancer Res., 54: 2121-2124, 1994.
4. Phillips, T. L., Levin, V. A., Ahn, D. K., Gutin, P. H., Davis, R. L., Wilson, C. B., Prados, M. D., Wara, W. M., and Flam, M. S. Evaluation of bromodeoxyuridine in glioblastoma multiforme: a Northern California Cancer Center Phase 11 study. Int. J. Radiat. Oncol. Biol. Phys., 21: 709-714, 1991.
5. Dolbeare, F., Gratzner, H., Pallavicini, M. G., and Gray, J. W. Flow cytometric measurement of total DNA content and incorporated bromodeoxyuridine. Proc. Natl. Acad. Sci. USA, 80: 5573-5577, 1983.
6. Begg, A. C., McNally, N. J., Shrieve, D. C., and Karcher, H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry, 6: 620-626, 1985.
7. Wilson, G. D., McNally, N. J., Dunphy, E., Karcher, H., and Pfragner, R. The labelling index of human and mouse tumours assessed by bromodeoxyuridine staining in vitro and in vivo and flow cytometry. Cytometry, 6: 641-647, 1985.
8. Rew, D. A., Campbell, I. D., Taylor, I., and Wilson, G. D. Proliferation indices of invasive breast carcinomas after in vivo 5-bromo-2′ -deoxyuridine labelling: a flow cytometric study of 75 tumours. Br. J. Surg., 79: 335-339, 1992.
9. Gratzner, H. G. Monoclonal antibody to 5-bromo- and 5-iododeoxyuridine: a new reagent for detection of DNA replication. Science (Wash. DC), 218: 474-475, 1982.
10. Jain, R. K. Transport of molecules in the tumor interstitium: a review. Cancer Res., 47: 3039-3051, 1987.
11. Jain, R. K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Delivery Rev., 26: 71-90, 1997.
12. Tannock, I. F., Lee, C. M., Tunggal, J. K., Cowan, D. S., and Egorin, M. J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res., 8: 878-884, 2002.
13. Brown, J. M. Evidence for acutely hypoxic cells in mouse tumours and a possible mechanism of reoxygenation. Br. J. Radiol., 52: 650-656, 1979.
14. Durand, R. E., and LePard, N. E. Contribution of transient blood flow to tumour hypoxia in mice. Acta Oncol., 34: 317-323, 1995.
15. Chaplin, D. I., Durand, R. E., and Olive, P. L. Acute hypoxia in tumour: implications for modifiers of radiation effects. Int. J. Radiat. Oncol. Biol. Phys., 12: 1279-1282, 1986.
16. Minchinton, A. I., Durand, R. E., and Chaplin, D. J. Intermittent blood flow in the KHT sarcoma-flow cytometry studies using Hoechst 33342. Br. J. Cancer, 62: 195-200, 1990.
17. Cowan, D. S. M., Hicks, K. O., and Wilson, W. R. Multicellular membranes as an in vitro model for extravascular diffusion in tumours. Br. J. Cancer, 74: S28-S31, 1996.
18. Kyle, A. H., Chan, C. T. O., and Minchinton, A. I. Characterisation of three dimensional tissue cultures using electrical impedance spectroscopy. Biophys. J., 76, 2640-2648, 1999.
19. Minchinton, A. I., Wendt, K. R., Clow, K. A., and Fryer, K. H. Multilayers of cells growing on a permeable support: an in vitro tumour model. Acta Oncol., 36: 13-16, 1997.
20. Peschke, P., Klein, V., Wolber, G., Friedrich, E., and Hahn, E. W. Morphometric analysis of bromodeoxyuridine distribution and cell density in the rat Dunning prostate tumor R3327-AT1 following treatment with radiation and/or hyperthermia. Histol. Histopathol., 14: 461-469, 1999.
21. Sham, E., and Durand, R. E. Repopulation characteristics and cell kinetic parameters resulting from multi-fraction irradiation of xenograft tumors in SCID mice. Int. J. Radiat. Oncol. Biol. Phys., 43: 617-622, 1999.
22. Rodriguez, R., Ritter, M. A., Fowler, J. F., and Kinsella, T. J. Kinetics of cell labeling and thymidine replacement after continuous infusion of halogenated pyrimidines in vivo. Int. J. Radiat. Oncol. Biol. Phys., 29: 105-113, 1994.
23. Tsang, R. W., Fyles, A. W., Milosevic, M., Syed, A., Pintilie, M., Levin, W., and Manchul, L. A. Interrelationship of proliferation and hypoxia in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys., 46: 95-99, 2000.
24. Zackrisson, B., Flygare, P., Gustafsson, H., Sjostrom, B., and Wilson, G. D. Cell kinetic changes in human squamous cell carcinomas during radiotherapy studied using the in vivo administration of two halogenated pyrimidines. Eur. J. Cancer, 38: 1100-1106, 2002.
25. Kinsella, T. J., Mitchell, J. B., Russo, A., Aiken, M., Morstyn, G., Hsu, S. M., Rowland, J., and Glatstein, E. Continuous intravenous infusions of bromodeoxyuridine as a clinical radiosensitizer. J. Clin. Oncol., 2: 1144-1150, 1984.
26. Kyle, A. H., and Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol., 43: 213-220, 1999.
27. Hicks, K. O., Fleming, Y., Siim, B. G., Koch, C. J., and Wilson, W. R. Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys., 42: 641-649, 1998.
28. Tunggal, J. K., Melo, T., Ballinger, J. R., and Tannock, I. F. The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layers. Int. J. Cancer, 86: 101-107, 2000.
29. Hicks, K. O., Pruijn, F. B., Baguley, B. C., and Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther., 297: 1088-1098, 2001.
30. Sutherland, R. M. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (Wash. DC), 240: 177-184, 1988.
31. Olive, P. L., and Durand, R. E. Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev., 13: 121-138, 1994.